mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say
Pharmaceutical partners Moderna and Merck announced on Wednesday that their novel mRNA-based vaccine-individually tailored to target a patient's unique cancer mutations-was effective in a late-stage clinical trial of patients with melanoma, one of the deadliest forms of skin cancer.
The announcement was scant on details, but if the success holds, it stands to realize the high aspirations for both mRNA vaccines and individualized cancer-targeting medicines in cancer therapy, providing a first success for both treatment types.
The Phase 3 trial included 1,137 patients who had stage IIB-IV melanoma that had been surgically removed prior to their treatment in the trial. Patients were randomized two-to-one to receive either a combination treatment of the tailored mRNA vaccine (intismeran or mRNA-4157) with Merck's established monoclonal antibody cancer treatment Keytruda, or they received treatment with Keytruda alone. Both patient groups were treated for about a year. The trial was placebo-controlled and double-blind, meaning neither the doctors nor the patients knew which treatment patients were randomly assigned to receive.